The pharmaceutical industry stands at a critical juncture, where the urgent need for faster, more sustainable, and patient-focused solutions is driving unprecedented change, as vividly demonstrated at the DCAT Summit held on June 4–5 in Lugano, Switzerland. Under the compelling theme "Expedition
Imagine a future where medical materials not only mimic the softness and resilience of human tissue but also heal themselves, all while being sourced directly from nature’s blueprint. At the University of Utah, a groundbreaking discovery has brought this vision closer to reality through
In a striking move that underscores the growing emphasis on domestic manufacturing in the biopharmaceutical sector, Amgen, a titan in the American biotech landscape, has committed a substantial $650 million to expand its biologics facility in Juncos, Puerto Rico. This investment is not merely a
Heart failure remains a formidable challenge in modern medicine, affecting millions globally and often leading to a diminished quality of life due to the heart's inability to pump blood effectively after injury. A groundbreaking development has emerged with the U.S. Food and Drug Administration
Lipid reprogramming has emerged as a critical frontier in understanding and treating clear cell renal cell carcinoma (ccRCC), the predominant subtype of kidney cancer that accounts for a significant portion of cases worldwide. This metabolic transformation, where tumor cells drastically alter how
Imagine a world where a deadly brain cancer diagnosis in a child no longer carries the grim prognosis it does today, where a non-invasive technology could breach the brain’s natural defenses just long enough to deliver life-saving drugs directly to the tumor. This vision is becoming a tangible
